PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v7i5.5245ArticleCurrent Status and Clinical Research Progress of Immunotherapy for Advanced Gastric Cancerhttps://artdesignp.com/journal/PAR/7/5/10.26689/par.v7i5.5245WangJiaxin2023752023-09-25Advanced gastric cancer is a common digestive system tumor, and its treatment has always been a difficult problem. In recent years, with the rapid development of immunotherapy, the treatment effect of advanced gastric cancer has been significantly improved. This article introduces the current status and clinical research progress of immune checkpoint inhibitors in advanced gastric cancer. Commonly used immunotherapy methods include chemical drug therapy, biological therapy, and gene therapy, among which the immune checkpoint inhibitors are currently one of the most popular immunotherapy methods, including nivolumab, pembrolizumab, and atezolizumab, which target programmed death ligand 1 (PD-L1) low expression (1%–49%) and PD-L1 high expression (≥50%). The results of clinical studies have shown that immunotherapy can significantly prolong the survival of patients with advanced gastric cancer while having lower toxic side effects and better tolerance. However, immunotherapy also has some problems, such as drug resistance and repeated infection. Future research directions include exploring new immunotherapy methods, combination therapy, and individualized therapy.

Jiang Z, Zhou A, 2023, Current Status and Progress of First-Line Immunotherapy for Advanced Gastric Cancer. Chinese Oncology Clinic, 50(4): 206–211.

Zhang L, Zhao Y, Yu X, et al., 2022, Comparative Analysis of the Efficacy of Different First-Line and Later-Line Treatment Options for Advanced Gastric Cancer. Modern Oncology, 30(22): 4113–4119.

Zhang Y, Han Y, 2022, Research Progress on Biomarkers Related to the Efficacy of PD-1/PD-L1 Inhibitors Combined with Chemotherapy in the First-Line Treatment of Advanced Gastric Cancer. Chinese Oncology Clinic, 49(19): 1021–1026.

Zhao H, Hu H, Xing Y, et al., 2022, Research Progress of Combination Therapy with Immune Checkpoint PD-1/PDL1 Inhibitors in Advanced Gastric Cancer. Chinese Oncology Clinic, 49(18): 958–962.

Chen Y, Liu M, Li Q, et al., 2022, Research Status of Clinical Immunotherapy and Immune Checkpoint Inhibitors for Advanced Gastric Cancer. Modern Digestive and Interventional Diagnosis and Treatment, 27(9): 1219–1223.

Zhou L, Liu L, Ren X, 2021, Current Status and Progress of Immunotherapy for Advanced Gastric Cancer and Gastroesophageal Junction Cancer. Chinese Journal of Cancer Biotherapy, 28(10): 1041–1048.

Zhang X. Effects of PD-L1 Expression, EBV and TMB on the Efficacy of Immune Checkpoint Inhibitors in Advanced Gastric Cancer that Failed Chemotherapy. 2022, Nanchang University.

Li L. Study on the Curative Effect and Prognostic Value of SII and PNI in Patients with Advanced Gastric Cancer Receiving Immune Checkpoint Inhibitor Therapy. 2022, Qingdao University.

Hou L, Wang Z, Yang T, et al., 2022, Current Status and Progress of PD-1 Immune Checkpoint Inhibitors in Gastric Cancer Immunotherapy. Tumor, 42(5): 314–324.

Pan Y, Si H, Deng G, et al., 2022, Association of Derived Neutrophil-to-Lymphocyte Ratio with Survival Outcomes in Advanced Gastric Cancer Patients Treated with PD-1 Inhibitors. Academic Journal of Chinese PLA Medical School, 43(3): 312–317. https://doi.org/10.3969/j.issn.2095-5227.2022.03.013

Wang Y, Zheng S, 2021, Research Progress of Anti-Angiogenesis Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Gastric Cancer. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine, 31(7): 687–690.

Shan Y, Liang P, Lu Y, et al., 2021, Meta-Analysis of the Effectiveness and Safety of Immune Checkpoint Inhibitors in the Treatment of Advanced Gastric Cancer or Esophagogastric Junction Cancer. Tumor Prevention and Treatment Research, 48(2): 166–172.

Li J, Ye S, Han C, et al., 2023, Effect of Immune Checkpoint Inhibitors Combined with Chemotherapy or Antiangiogenic Drugs as Second-Line Treatment of Advanced Gastric Cancer and Gastroesophageal Junction Adenocarcinoma. Academic Journal of Chinese PLA Medical School, preprint. https://doi.org/10.12435/j.issn.2095-5227.2023.036

Zhang J. Comparison of the Efficacy of Immune Checkpoint Inhibitors or Apatinib Combined with Chemotherapy for Maintenance Therapy of Advanced Gastric Cancer. 2023, Nanchang University.

Lu J, Du S, Zhao C, et al., 2023, Prognostic Factors of First-Line Immune Checkpoint Inhibitor Combined with Chemotherapy in Advanced Gastric Cancer and Its Impact on Second-Line Chemotherapy. Chinese Oncology Clinic, 50(1): 22–29.

Zhao H, Hu H, Xing Y, et al., 2022, Research Progress of Combination Therapy with Immune Checkpoint PD-1/PDL1 Inhibitors for Advanced Gastric Cancer. Chinese Oncology Clinic, 49(18): 958–962.

Chen Y, Liu M, Li Q, et al., 2022, Research Status of Clinical Immunotherapy and Immune Checkpoint Inhibitors for Advanced Gastric Cancer. Modern Digestive and Interventional Diagnosis and Treatment, 27(9): 1219–1223.

Pan Y, Si H, Deng G, et al., 2022, Predictive Value of Albumin and ANPG in Advanced Gastric Cancer Patients Treated with Anti-PD1 Therapy. Academic Journal of Chinese PLA Medical School, 43(9): 943–948. https://doi.org/10.3969/j.issn.2095-5227.2022.09.006